<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/BECA2763-0902-40AA-8DB2-836A5731CF58"><gtr:id>BECA2763-0902-40AA-8DB2-836A5731CF58</gtr:id><gtr:name>Brunel University</gtr:name><gtr:address><gtr:line1>Brunel University</gtr:line1><gtr:line4>Uxbridge</gtr:line4><gtr:line5>Middlesex</gtr:line5><gtr:postCode>UB8 3PH</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/33699F48-13B6-4BDA-AED4-274FF3B13DE8"><gtr:id>33699F48-13B6-4BDA-AED4-274FF3B13DE8</gtr:id><gtr:name>Wuhan University</gtr:name><gtr:address><gtr:line1>129 LuoYu Road</gtr:line1><gtr:line4>Wuhan</gtr:line4><gtr:line5>Hubei</gtr:line5><gtr:postCode>430072</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>China</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Biochemistry</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/BECA2763-0902-40AA-8DB2-836A5731CF58"><gtr:id>BECA2763-0902-40AA-8DB2-836A5731CF58</gtr:id><gtr:name>Brunel University</gtr:name><gtr:address><gtr:line1>Brunel University</gtr:line1><gtr:line4>Uxbridge</gtr:line4><gtr:line5>Middlesex</gtr:line5><gtr:postCode>UB8 3PH</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/33699F48-13B6-4BDA-AED4-274FF3B13DE8"><gtr:id>33699F48-13B6-4BDA-AED4-274FF3B13DE8</gtr:id><gtr:name>Wuhan University</gtr:name><gtr:address><gtr:line1>129 LuoYu Road</gtr:line1><gtr:line4>Wuhan</gtr:line4><gtr:line5>Hubei</gtr:line5><gtr:postCode>430072</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>China</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/EFBAD219-504A-49BA-9A3A-660ACD27F789"><gtr:id>EFBAD219-504A-49BA-9A3A-660ACD27F789</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:surname>Leadlay</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G1001687"><gtr:id>F724F7D3-06C9-4FCB-B45A-F14BA3844B07</gtr:id><gtr:title>Safer aminoglycoside therapeutics by biosynthetic engineering</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1001687</gtr:grantReference><gtr:abstractText>Bacterial infections in hospital patients can lead to sepsis, in which an overwhelming infection of the bloodstream by toxin-producing bacteria becomes life-threatening. Very few new antibiotics are being developed, and so the established antibiotic gentamicin, discovered over 40 years ago, is likely to remain a vital mainstay in efforts to combat sepsis. Unfortunately there are real dangers associated with its use: a large percentage of patients treated with gentamicin, or related antibiotics, develop acute kidney failure (nephrotoxicity). The drug may also cause irreversible hearing loss (ototoxicity). Treatment is very costly because patients have to be closely monitored to minimise these severe side-effects. 
Sustained efforts are being made to research ways of minimising the side-effects of gentamicin, by altering the dosing strategy for example; and to understand the biochemical mechanisms by which the kidney and the inner ear are damaged. Unfortunately the gentamicin used clinically is a mixture of compounds and different batches of commercial gentamicin have different amounts of each component. The individual components can be separated on a small scale but it has not been economically viable to do this commercially. It was believed that they were equally effective and equally toxic, but in 2006, researchers in the USA re-tested each of the main components of gentamicin (known as C1, C1a, C2 and C2a) and showed that, surprisingly, purified component C2 is fully effective as an antibiotic - but is apparently not nephrotoxic at all (at least in rats). 
The aim of this project is to decipher all of the individual steps of the late stages of gentamicin biosynthesis, to identify which enzymes are involved, and to devise strategies for engineering specific genes in the pathway in order to divert production towards a single component (such as C2). The ready availability of single components of the gentamicin complex by fermentation would encourage potentially safer formulations of the antibiotic to be tested. Since gentamicins and related aminoglycosides are also promising agents for the correction of certain human genetic diseases, such as cystic fibrosis and the muscle-wasting disease Duchenne muscular dystrophy, there could be wider medical benefits too.</gtr:abstractText><gtr:technicalSummary>Gentamicin and related aminoglycosides are valuable broad-spectrum antibiotics, active against both Gram positive and Gram negative bacteria. Gentamicin itself is being used increasingly to combat hospital-acquired sepsis, despite the well-known nephrotoxicity and ototoxicity associated with its use. Unfortunately, most studies aimed at clarifying the mechanisms of toxicity and alleviating these side effects have not taken into account that gentamicin as used clinically is a mixture of four main components with subtle structural differences. In a recent study, component C2 was reported to be non-nephrotoxic (in rats) while retaining the antibacterial effectiveness of the other components. Meanwhile, sequencing of multiple aminoglycoside biosynthetic gene clusters has made available a wealth of information on the number and type of enzymes involved. The first aim of this project is to analyse each enzyme in the late stages of the pathway and define its specificity, role and mechanism of action. A combined genetic and biochemical approach will be required: specific gene deletion will be used to gain insight into the exact sequence of biochemical events and identify branchpoints. The putative intermediates accumulated in such blocked mutants will be identified and characterised. These compounds will also serve as potential substrates for individual recombinant enzymes expressed from the genes of the pathway. Expression of sets of late-stage gentamicin biosynthetic genes in heterologous host strains will be used to complement the in vitro studies. The pathway contains unusual enzymes, including ones catalysing ring deoxygenation, and a potentially methylcobalamin-dependent C-methyltransferase of the so-called radical SAM family. We aim to clarify the mechanism of action of these enzymes. As the detailed gentamicin pathway is elucidated, we aim to design and test strains that produce, as far as possible, single component gentamicins instead of mixtures.</gtr:technicalSummary><gtr:fund><gtr:end>2014-03-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>396217</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Brunel University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute for Bioengineering (BIB)</gtr:department><gtr:description>SEPARATION OF GENTAMICINS BY CCC</gtr:description><gtr:id>C41E01EF-1218-44D7-9F95-505FA8999EA8</gtr:id><gtr:impact>The chief output is a supply of homogenous gentamicin samples comprising all the four major components of clinically-used gentamicin mixtures. In the near future (1st/2nd Q 2014) we expect to start separating novel metabolites obtained from blocked mutants</gtr:impact><gtr:partnerContribution>DR IAN GARRARD AND COLLEAGUES USE THEIR PROPRIETARY CENTRIFUGAL COUNTER-CURRENT CHROMATOGRAPHY TO SEPARATE HYDROPHILIC NATURAL PRODUCTS SUCH AS THE GENTAMICINS</gtr:partnerContribution><gtr:piContribution>WE SUPPLY BRUNEL WITH FERMENTATION SUPERNATANTS CONTAINING GENTAMICINS AND RELATED METABOLITES</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Wuhan</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>State Key Laboratory for Combinatorial Biosynthesis</gtr:department><gtr:description>Gentamicin biosynthesis</gtr:description><gtr:id>36B88AEC-BEFB-4BBF-A7E7-B2F86D581556</gtr:id><gtr:impact>The Chinese Government has agreed to fund travel and subsistence for members of the Cambridge team to visit Wuhan for periods of two months each over the next three years, for joint work and scientific discussions.
The first two mss arising from this work are in preparation and the first of these will be submitted to Chemistry and Biology within the next two weeks. We are also considering whether the discoveries we have made warrant the lodging of a patent application before the publication is made.</gtr:impact><gtr:partnerContribution>Wuhan is conducting the wholesale genetic knockouts of individual genes for gentamicin biosynthesis, construction and analysis of double mutants, and attempts to generate high-yielding strains by conventional mutagenesis. All mutants are being scrutinised for (novel) metabolites and purified metabolites supplied to Cambridge for in vitro work.</gtr:partnerContribution><gtr:piContribution>We will conduct all in vitro experiments in investigation of the biosynthetic pathway to gentamicin antibiotics; and undertake the heterologous expression of (subsets) of gentamicin biosynthetic genes in other actinomycete hosts; as well as refactoring the gene cluster to produce monocomponent gentamicins of lower nephrotoxicity</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>35000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>University of Cambridge Gates Foundation Studentships</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>Bill and Melinda Gates Foundation</gtr:fundingOrg><gtr:id>4DDFAF1A-1CF9-40C5-8928-71921797C35E</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>387097</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Towards safer aminoglycoside therapeutics</gtr:description><gtr:end>2018-03-02</gtr:end><gtr:fundingOrg>MRC-UK</gtr:fundingOrg><gtr:fundingRef>MR/MO19020/1</gtr:fundingRef><gtr:id>1F357BA0-ECFE-4266-9398-FFD6136C22E6</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>expanded collection of purified gentamicins and gentamicin-related metabolites, arising from blocked mutants of the gentamicin producing organism Micromonospora echinospora DSM 43036</gtr:description><gtr:id>F41F4F1A-96AD-4651-ACAC-72BD189CF4BF</gtr:id><gtr:impact>these were milestones successfully achieved in this project.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>novel gentamicin samples</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/ED68ACE3-FA5F-49DE-8A49-170B11E92C0F"><gtr:id>ED68ACE3-FA5F-49DE-8A49-170B11E92C0F</gtr:id><gtr:title>Delineating the biosynthesis of gentamicin x2, the common precursor of the gentamicin C antibiotic complex.</gtr:title><gtr:parentPublicationTitle>Chemistry &amp; biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c5b4ef969040b66fb3a85f89c05a4178"><gtr:id>c5b4ef969040b66fb3a85f89c05a4178</gtr:id><gtr:otherNames>Huang C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1074-5521</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DEFE9C76-0674-4DF5-8C23-3A446FA7BDDB"><gtr:id>DEFE9C76-0674-4DF5-8C23-3A446FA7BDDB</gtr:id><gtr:title>Specificity and promiscuity at the branch point in gentamicin biosynthesis.</gtr:title><gtr:parentPublicationTitle>Chemistry &amp; biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b615a7b83359d66cdfac7d6df08df973"><gtr:id>b615a7b83359d66cdfac7d6df08df973</gtr:id><gtr:otherNames>Guo J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1074-5521</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1001687</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>